

CLAIMS AMENDMENTS

Please amend claims 1, and 66-150, as shown below. All other claims are unchanged.

1. (currently amended) A preparation for topically delivering and localizing at least one therapeutic agents, comprising:

a vasoconstrictor for retarding vascular dispersion of a therapeutic agent, selected from the vasoconstrictor group consisting of at least one of: *phenylephrine, ephedrine sulfate, epinephrine, naphazoline, and oxymetazoline*; and

a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin, selected from the penetration enhancer group consisting of at least one of: *lecithin* and *dimethylsulfoxide*; wherein:

said therapeutic agent is selected from ~~the therapeutic agent group consisting of~~ at least one of therapeutic agent in at least one of the following therapeutic agent groups:

(a) a local anesthetic selected from the group consisting of: *bupivacaine, mepivacaine, levobupivacaine, ropivacaine, chloroprocaine, procaine, lidocaine, etidocaine, benzocaine, tetracaine, and prilocaine*;

(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, and tolmetin*;

22 | _____ (c) a long-acting non-steroidal anti-inflammatory agent_
 23 | selected from the group consisting of: piroxicam, celecoxib,
 24 | meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac,
 25 | and valdecoxib;~~and~~
 26 | _____ (d) an antiviral agent selected from the group consisting
 27 | of: 2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and
 28 | docosanol.

1 2. (withdrawn, original) The preparation of claim 1, said
 2 vasoconstrictor comprising *phenylephrine*.

1 3. (withdrawn, original) The preparation of claim 2, wherein:
 2 a clinical concentration of said *phenylephrine* is at least
 3 approximately 0.125%; and
 4 said clinical concentration of said *phenylephrine* is at
 5 most approximately 1.0%.

1 4. (withdrawn, original) The preparation of claim 3, wherein
 2 said clinical concentration of said *phenylephrine* is
 3 approximately 0.5%.

1 5. (withdrawn, original) The preparation of claim 1, said
 2 vasoconstrictor comprising a vasoconstrictor selected from the
 3 vasoconstrictor group consisting of: *ephedrine sulfate*,
 4 *epinephrine*, *naphazoline*, and *oxymetazoline*.

1 6. (withdrawn, original) The preparation of claim 1, said
 2 penetration enhancer comprising *dimethylsulfoxide*.

1 7. (withdrawn, original) The preparation of claim 6, wherein

2 a clinical concentration of said *dimethylsulfoxide* is at most
3 approximately 10%.

1 8. (withdrawn, original) The preparation of claim 7, wherein
2 said clinical concentration of said *dimethylsulfoxide* is
3 approximately 10%.

1 9. (withdrawn, original) The preparation of claim 1, said
2 penetration enhancer comprising *lecithin*.

1 10. (withdrawn, original) The preparation of claim 9, said
2 penetration enhancer further comprising *ethoxy diglycol*.

1 11. (withdrawn, original) The preparation of claim 9, wherein:
2 a clinical concentration of said *lecithin* is at least
3 approximately 2%; and

4 said clinical concentration of said *lecithin* is at most
5 approximately 50%.

1 12. (withdrawn, original) The preparation of claim 11,
2 wherein:

3 said clinical concentration of said *lecithin* is
4 approximately 10% to 12%.

1 13. (withdrawn, original) The preparation of claim 1:
2 said vasoconstrictor comprising *phenylephrine*; and
3 said penetration enhancer comprising *dimethylsulfoxide*.

1 14. (withdrawn, original) The preparation of claim 13,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least

4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%; and

7 a clinical concentration of said *dimethylsulfoxide* is at
8 most approximately 10%.

1 15. (withdrawn, original) The preparation of claim 14,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%; and

5 said clinical concentration of said *dimethylsulfoxide* is
6 approximately 10%.

1 16. (withdrawn, original) The preparation of claim 13,
2 wherein:

3 a ratio of a clinical concentration of said
4 *dimethylsulfoxide* to a clinical concentration of said
5 *phenylephrine* is at most approximately 40 to 1.

1 17. (withdrawn, original) The preparation of claim 1:

2 said vasoconstrictor comprising *phenylephrine*; and

3 said penetration enhancer comprising *lecithin*.

1 18. (withdrawn, original) The preparation of claim 17, said
2 penetration enhancer further comprising *ethoxy diglycol*.

1 19. (withdrawn, original) The preparation of claim 17,

2 wherein:

3 a clinical concentration of said *phenylephrine* is at least

4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%; and

7 a clinical concentration of said *lecithin* is at most
8 approximately 50%.

1 20. (withdrawn, original) The preparation of claim 19,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%; and

5 said clinical concentration of said *lecithin* is
6 approximately 10% to 12%.

1 21. (withdrawn, original) The preparation of claim 17,
2 wherein:

3 a ratio of a clinical concentration of said *lecithin* to a
4 clinical concentration of said *phenylephrine* is at most
5 approximately 200 to 1.

1 22. (withdrawn, original) The preparation of claim 1, further
2 comprising:

3 said therapeutic agent.

1 23. (withdrawn, original) The preparation of claim 22,
2 particularly for relieving pain, comprising:

3 said therapeutic agent comprising a therapeutic pain-
4 relieving agent;

5 said penetration enhancer for facilitating penetration of

6 said therapeutic pain-relieving agent and said vasoconstrictor
7 through the patient's skin; and

8 said vasoconstrictor for retarding vascular dispersion of
9 said therapeutic agent.

1 24. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a local anesthetic.

1 25. (withdrawn, original) The preparation of claim 24, said
2 local anesthetic comprising *bupivacaine*.

1 26. (withdrawn, original) The preparation of claim 25,
2 wherein:

3 a clinical concentration of said *bupivacaine* is at least
4 approximately 2%; and

5 said clinical concentration of said *bupivacaine* is at most
6 approximately 10%.

1 27. (withdrawn, original) The preparation of claim 26, wherein
2 said clinical concentration of said *bupivacaine* is approximately
3 5%.

1 28. (withdrawn, original) The preparation of claim 24, said
2 local anesthetic comprising a local anesthetic selected from the
3 local anesthetic group consisting of: *mepivacaine*,
4 *levobupivacaine*, *ropivacaine*, *chloroprocaine*, *procaine*,
5 *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and *prilocaine*.

1 29. (withdrawn, original) The preparation of claim 23, said

2 therapeutic pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory
4 agent.

1 30. (withdrawn, original) The preparation of claim 29, said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 comprising *ketoprofen*.

1 31. (withdrawn, original) The preparation of claim 30,
2 wherein:

3 a clinical concentration of said *ketoprofen* is at least
4 approximately 5%; and

5 said clinical concentration of said *ketoprofen* is at most
6 approximately 20%.

1 32. (withdrawn, original) The preparation of claim 31, wherein
2 said clinical concentration of said *ketoprofen* is approximately
3 10%.

1 33. (withdrawn, original) The preparation of claim 29, said
2 quick-onset, short-acting non-steroidal anti-inflammatory agent
3 comprising a quick-onset, short-acting non-steroidal anti-
4 inflammatory agent selected from the quick-onset, short-acting
5 non-steroidal anti-inflammatory agent group consisting of:
6 *diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen,*
7 *ibuprofen, indomethacin, and tolmetin.*

1 34. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a long-acting non-steroidal anti-inflammatory agent.

1 35. (withdrawn, original) The preparation of claim 34, said
2 long-acting non-steroidal anti-inflammatory agent comprising
3 *piroxicam*.

1 36. (withdrawn, original) The preparation of claim 35,
2 wherein:

3 a clinical concentration of said *piroxicam* is at least
4 approximately 0.5%; and

5 said clinical concentration of said *piroxicam* is at most
6 approximately 4%.

1 37. (withdrawn, original) The preparation of claim 36, wherein
2 said clinical concentration of said *piroxicam* is approximately
3 1.0%.

1 38. (withdrawn, original) The preparation of claim 34, said
2 long-acting non-steroidal anti-inflammatory agent comprising a
3 long-acting non-steroidal anti-inflammatory agent selected from
4 the long-acting non-steroidal anti-inflammatory agent group
5 consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*,
6 *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

1 39. (withdrawn, original) The preparation of claim 23, said
2 therapeutic pain-relieving agent comprising:

3 a local anesthetic; and

4 a quick-onset, short-acting non-steroidal anti-inflammatory
5 agent.

1 40. (withdrawn, original) The preparation of claim 39:
 2 said local anesthetic comprising *bupivacaine*; and
 3 said quick-onset, short-acting non-steroidal anti-
 4 inflammatory agent comprising *ketoprofen*.

1 41. (withdrawn, original) The preparation of claim 23, said
 2 therapeutic pain-relieving agent comprising:
 3 a local anesthetic; and
 4 a long-acting non-steroidal anti-inflammatory agent.

1 42. (withdrawn, original) The preparation of claim 41:
 2 said local anesthetic comprising *bupivacaine*; and
 3 said long-acting non-steroidal anti-inflammatory agent
 4 comprising *piroxicam*.

1 43. (withdrawn, original) The preparation of claim 23, said
 2 therapeutic pain-relieving agent comprising:
 3 a quick-onset, short-acting non-steroidal anti-inflammatory
 4 agent; and
 5 a long-acting non-steroidal anti-inflammatory agent.

1 44. (withdrawn, original) The preparation of claim 43:
 2 said quick-onset, short-acting non-steroidal anti-
 3 inflammatory agent comprising *ketoprofen*; and
 4 said long-acting non-steroidal anti-inflammatory agent
 5 comprising *piroxicam*.

1 45. (withdrawn, original) The preparation of claim 23, said
 2 therapeutic pain-relieving agent comprising:

3 a local anesthetic;
 4 a quick-onset, short-acting non-steroidal anti-inflammatory
 5 agent; and
 6 a long-acting non-steroidal anti-inflammatory agent.

1 46. (withdrawn, original) The preparation of claim 45:

2 said local anesthetic comprising *bupivacaine*;
 3 said quick-onset, short-acting non-steroidal anti-
 4 inflammatory agent comprising *ketoprofen*; and
 5 said long-acting non-steroidal anti-inflammatory agent
 6 comprising *piroxicam*.

1 47. (withdrawn, original) The preparation of claim 46,

2 wherein:

3 a clinical concentration of said *bupivacaine* is at least
 4 approximately 2%;

5 said clinical concentration of said *bupivacaine* is at most
 6 approximately 10%;

7 a clinical concentration of said *ketoprofen* is at least
 8 approximately 5%;

9 said clinical concentration of said *ketoprofen* is at most
 10 approximately 20%;

11 a clinical concentration of said *piroxicam* is at least
 12 approximately 0.5%; and

13 said clinical concentration of said *piroxicam* is at most
 14 approximately 4%.

1 48. (withdrawn, original) The preparation of claim 47,
2 wherein:

3 said clinical concentration of said *bupivacaine* is
4 approximately 5%;

5 said clinical concentration of said *ketoprofen* is
6 approximately 10%; and

7 said clinical concentration of said *piroxicam* is
8 approximately 1.0%

1 49. (withdrawn, original) The preparation of claim 22,
2 particularly for treating a viral disease, comprising:

3 said therapeutic agent comprising an antiviral agent;

4 said penetration enhancer for facilitating penetration of
5 said antiviral agent and said vasoconstrictor through the
6 patient's skin; and

7 said vasoconstrictor for retarding vascular dispersion of
8 said antiviral agent.

1 50. (withdrawn, original) The preparation of claim 49, said
2 antiviral agent comprising *2-deoxy-d-glucose*.

1 51. (withdrawn, original) The preparation of claim 50,
2 wherein:

3 a clinical concentration of said *2-deoxy-d-glucose* is at
4 least approximately 0.1%; and

5 said clinical concentration of said *2-deoxy-d-glucose* is at
6 most approximately 0.4%.

1 52. (withdrawn, original) The preparation of claim 51,
2 wherein:

3 said clinical concentration of said *2-deoxy-d-glucose* is
4 approximately 0.2%.

1 53. (withdrawn, original) The preparation of claim 49, said
2 antiviral agent comprising an antiviral agent selected from the
3 antiviral agent group consisting of: *podofilox*, *acyclovir*,
4 *penciclovir*, and *docosanol*.

1 54. (withdrawn, original) The preparation of claim 23,
2 particularly for relieving pain from a viral disease and
3 treating the viral disease, comprising:

4 said therapeutic agent further comprising an antiviral
5 agent;

6 said penetration enhancer for further facilitating
7 penetration of said antiviral agent through the patient's skin;
8 and

9 said vasoconstrictor for further retarding vascular
10 dispersion of said antiviral agent.

1 55. (withdrawn, original) The preparation of claim 54, said
2 antiviral agent comprising *2-deoxy-d-glucose*.

1 56. (withdrawn, original) The preparation of claim 55,
2 wherein:

3 a clinical concentration of said *2-deoxy-d-glucose* is at
4 least approximately 0.1%; and

5 said clinical concentration of said *2-deoxy-d-glucose* is at
6 most approximately 0.4%.

1 57. (withdrawn, original) The preparation of claim 56,
2 wherein:

3 said clinical concentration of said *2-deoxy-d-glucose* is
4 approximately 0.2%.

1 58. (withdrawn, original) The preparation of claim 54, said
2 antiviral agent comprising an antiviral agent selected from the
3 antiviral agent group consisting of: *podofilox*, *acyclovir*,
4 *penciclovir*, and *docosanol*.

1 59. (withdrawn, original) The preparation of claim 45:

2 said vasoconstrictor comprising *phenylephrine*;

3 said penetration enhancer comprising a penetration
4 enhancing agent selected from the penetration-enhancing agent
5 group consisting of *dimethylsulfoxide* and *lecithin*;

6 said local anesthetic comprising *bupivacaine*;

7 said quick-onset, short-acting non-steroidal anti-
8 inflammatory agent comprising *ketoprofen*; and

9 said long-acting non-steroidal anti-inflammatory agent
10 comprising *piroxicam*.

1 60. (withdrawn, original) The preparation of claim 59,
2 wherein:

3 a clinical concentration of said *phenylephrine* is at least
4 approximately 0.125%;

5 said clinical concentration of said *phenylephrine* is at
6 most approximately 1.0%;

7 a clinical concentration of said *dimethylsulfoxide* is at
8 most approximately 10%;

9 a clinical concentration of said *lecithin* is at most
10 approximately 50%;

11 a clinical concentration of said *bupivacaine* is at least
12 approximately 2%;

13 said clinical concentration of said *bupivacaine* is at most
14 approximately 10%;

15 a clinical concentration of said *ketoprofen* is at least
16 approximately 5%;

17 said clinical concentration of said *ketoprofen* is at most
18 approximately 20%;

19 a clinical concentration of said *piroxicam* is at least
20 approximately 0.5%; and

21 said clinical concentration of said *piroxicam* is at most
22 approximately 4%.

1 61. (withdrawn, original) The preparation of claim 60,
2 wherein:

3 said clinical concentration of said *phenylephrine* is
4 approximately 0.5%;

5 said clinical concentration of said *bupivacaine* is
6 approximately 5%;

7 said clinical concentration of said *ketoprofen* is
 8 approximately 10%; and
 9 said clinical concentration of said *piroxicam* is
 10 approximately 1.0%.

1 62. (withdrawn, original) The preparation of claim 45,
 2 additionally for treating a viral disease, said therapeutic
 3 agent further comprising:
 4 an antiviral agent.

1 63. (withdrawn, original) The preparation of claim 62:
 2 said vasoconstrictor comprising *phenylephrine*;
 3 said penetration enhancer comprising a penetration
 4 enhancing agent selected from the penetration-enhancing agent
 5 group consisting of *dimethylsulfoxide* and *lecithin*;
 6 said local anesthetic comprising *bupivacaine*;
 7 said quick-onset, short-acting non-steroidal anti-
 8 inflammatory agent comprising *ketoprofen*;
 9 said long-acting non-steroidal anti-inflammatory agent
 10 comprising *piroxicam*; and
 11 said antiviral agent comprising *2-deoxy-d-glucose*.

1 64. (withdrawn, original) The preparation of claim 63,
 2 wherein:
 3 a clinical concentration of said *phenylephrine* is at least
 4 approximately 0.125%;
 5 said clinical concentration of said *phenylephrine* is at

6 most approximately 1.0%;

7 a clinical concentration of said *dimethylsulfoxide* is at

8 most approximately 10%;

9 a clinical concentration of said *lecithin* is at most

10 approximately 50%;

11 a clinical concentration of said *bupivacaine* is at least

12 approximately 2%;

13 said clinical concentration of said *bupivacaine* is at most

14 approximately 10%;

15 a clinical concentration of said *ketoprofen* is at least

16 approximately 5%;

17 said clinical concentration of said *ketoprofen* is at most

18 approximately 20%;

19 a clinical concentration of said *piroxicam* is at least

20 approximately 0.5%;

21 said clinical concentration of said *piroxicam* is at most

22 approximately 4%;

23 a clinical concentration of said *2-deoxy-d-glucose* is at

24 least approximately 0.1%; and

25 said clinical concentration of said *2-deoxy-d-glucose* is at

26 most approximately 0.4%.

1 65. (withdrawn, original) The preparation of claim 64,

2 wherein:

3 said clinical concentration of said *phenylephrine* is

4 approximately 0.5%;

5 said clinical concentration of said *bupivacaine* is

6 approximately 5%;

7 said clinical concentration of said *ketoprofen* is

8 approximately 10%;

9 said clinical concentration of said *piroxicam* is

10 approximately 1.0%; and

11 said clinical concentration of said *2-deoxy-d-glucose* is

12 approximately 0.2%.

1 66. (withdrawn, currently amended) A method of topically

2 delivering and localizing at least one therapeutic agents,

3 comprising:

4 using a vasoconstrictor for retarding vascular dispersion

5 of a therapeutic agent, selected from the vasoconstrictor group

6 consisting of at least one of: *phenylephrine*, *ephedrine sulfate*,

7 *epinephrine*, *naphazoline*, and *oxymetazoline*; in combination with

8 using a penetration enhancer for facilitating penetration

9 of said vasoconstrictor and said therapeutic agent through a

10 patient's skin, selected from the penetration enhancer group

11 consisting of at least one of: *lecithin* and *dimethylsulfoxide*;

12 wherein:

13 said therapeutic agent is selected from ~~the therapeutic~~

14 ~~agent group consisting of at least one of~~ therapeutic agent in at

15 least one of the following therapeutic agent groups:

(a) a local anesthetic selected from the group consisting of: *bupivacaine, mepivacaine, levobupivacaine, ropivacaine, chloroprocaine, procaine, lidocaine, etidocaine, benzocaine, tetracaine, and prilocaine*;

(b) a quick-onset, short-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *ketoprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, and tolmetin*;

(c) a long-acting non-steroidal anti-inflammatory agent selected from the group consisting of: *piroxicam, celecoxib, meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib, sulindac, and valdecoxib*; ~~and~~

(d) an antiviral agent selected from the group consisting of: *2-deoxy-d-glucose, podofilox, acyclovir, penciclovir, and docosanol*.

67. (withdrawn, currently amended) The method of claim 66 ,
~~said step of~~ using said vasoconstrictor further comprising ~~the~~
~~step of~~ using *phenylephrine*.

68. (withdrawn, currently amended) The method of claim 67,
 further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at
 least approximately 0.125%; and

using said clinical concentration of said *phenylephrine*, of
 at most approximately 1.0%.

1 69. (withdrawn, currently amended) The method of claim 68,
 2 further comprising ~~the step of~~ using said clinical concentration
 3 of said *phenylephrine*, of approximately 0.5%.

1 70. (withdrawn, currently amended) The method of claim 66 ,
 2 said ~~step of~~ using said vasoconstrictor further comprising ~~the~~
 3 ~~step of~~ using a vasoconstrictor selected from the
 4 vasoconstrictor group consisting of: *ephedrine sulfate*,
 5 *epinephrine*, *naphazoline*, and *oxymetazoline*.

1 71. (withdrawn, currently amended) The method of claim 66,
 2 said ~~step of~~ using said penetration enhancer further comprising
 3 ~~the step of~~ using *dimethylsulfoxide*.

1 72. (withdrawn, currently amended) The method of claim 71,
 2 further comprising ~~the step of~~ using a clinical concentration of
 3 said *dimethylsulfoxide*, of at most approximately 10%.

1 73. (withdrawn, currently amended) The method of claim 72,
 2 further comprising ~~the step of~~ using said clinical concentration
 3 of said *dimethylsulfoxide*, of approximately 10%.

1 74. (withdrawn, currently amended) The method of claim 66,
 2 said ~~step of~~ using said penetration enhancer further comprising
 3 ~~the step of~~ using comprising *lecithin*.

1 75. (withdrawn, currently amended) The method of claim 74,
 2 said ~~step of~~ using said penetration enhancer further comprising
 3 ~~the step of~~ using *ethoxy diglycol*.

1 76. (withdrawn, currently amended) The method of claim 74,

2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *lecithin*, of at
4 | least approximately 2%; and

5 | using said clinical concentration of said *lecithin*, of at
6 | most approximately 50%.

1 | 77. (withdrawn, currently amended) The method of claim 76,

2 | further comprising ~~the step of~~:

3 | using said clinical concentration of said *lecithin*, of
4 | approximately 10% to 12%.

1 | 78. (withdrawn, currently amended) The method of claim 66:

2 | said ~~step of~~ using said vasoconstrictor further comprising—
3 | ~~the step of~~ using *phenylephrine*; and

4 | said ~~step of~~ using said penetration enhancer further
5 | comprising ~~the step of~~ using *dimethylsulfoxide*.

1 | 79. (withdrawn, currently amended) The method of claim 78,

2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *phenylephrine*, of at
4 | least approximately 0.125%;

5 | using said clinical concentration of said *phenylephrine*, of
6 | at most approximately 1.0%; and

7 | using a clinical concentration of said *dimethylsulfoxide*,
8 | of at most approximately 10%.

1 | 80. (withdrawn, currently amended) The method of claim 79,

2 | further comprising ~~the steps of~~:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and

using said clinical concentration of said *dimethylsulfoxide*, of approximately 10%.

81. (withdrawn, currently amended) The method of claim 78, further comprising ~~the step of~~:

using a ratio of a clinical concentration of said *dimethylsulfoxide* to a clinical concentration of said *phenylephrine*, of at most approximately 40 to 1.

82. (withdrawn, currently amended) The method of claim 66:

~~said step of~~ using said vasoconstrictor further comprising ~~the step of~~ using *phenylephrine*; and
~~said step of~~ using said penetration enhancer further comprising ~~the step of~~ using *lecithin*.

83. (withdrawn, currently amended) The method of claim 82, ~~said step of~~ using said penetration enhancer further comprising ~~the step of~~ using *ethoxy diglycol*.

84. (withdrawn, currently amended) The method of claim 82, further comprising ~~the steps of~~:

using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and

using a clinical concentration of said *lecithin*, of at most

8 approximately 50%.

1 85. (withdrawn, currently amended) The method of claim 84,

2 further comprising ~~the steps of~~:

3 using said clinical concentration of said *phenylephrine*, of
4 approximately 0.5%; and

5 using said clinical concentration of said *lecithin*, of
6 approximately 10% to 12%.

1 86. (withdrawn, currently amended) The method of claim 82,

2 further comprising ~~the step of~~:

3 using a ratio of a clinical concentration of said *lecithin*
4 to a clinical concentration of said *phenylephrine*, of at most
5 approximately 200 to 1.

1 87. (withdrawn, currently amended) The method of claim 66,

2 further comprising ~~the step of~~:

3 using said therapeutic agent in combination with using said
4 vasoconstrictor and using said penetration enhancer.

1 88. (withdrawn, currently amended) The method of claim 87,

2 particularly for relieving pain:

3 said ~~step of~~ using said therapeutic agent further
4 comprising ~~the step of~~ using a therapeutic pain-relieving agent;
5 further comprising ~~the steps of~~:

6 using said penetration enhancer for facilitating
7 penetration of said therapeutic pain-relieving agent and said
8 vasoconstrictor through the patient's skin; and

9 using said vasoconstrictor for retarding vascular
10 dispersion of said therapeutic agent.

1 89. (withdrawn, currently amended) The method of claim 88,
2 | ~~said step of~~ using said therapeutic pain-relieving agent further
3 | ~~comprising the step of~~ using a local anesthetic.

1 90. (withdrawn, currently amended) The method of claim 89,
2 | ~~said step of~~ using said local anesthetic further comprising ~~the~~
3 | ~~step of~~ using *bupivacaine*.

1 91. (withdrawn, currently amended) The method of claim 90,
2 | further comprising ~~the steps of~~:

3 using a clinical concentration of said *bupivacaine*, of at
4 least approximately 2%; and

5 using said clinical concentration of said *bupivacaine*, of
6 at most approximately 10%.

1 92. (withdrawn, currently amended) The method of claim 91,
2 | further comprising ~~the step of~~ using said clinical concentration
3 | of said *bupivacaine*, of approximately 5%.

1 93. (withdrawn, currently amended) The method of claim 89,
2 | ~~said step of~~ using said local anesthetic further comprising ~~the~~
3 | ~~step of~~ using a local anesthetic selected from the local
4 anesthetic group consisting of: *mepivacaine*, *levobupivacaine*,
5 *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*,
6 *benzocaine*, *tetracaine*, and *prilocaine*.

1 94. (withdrawn, currently amended) The method of claim 88,

2 | ~~said step of~~ using said therapeutic pain-relieving agent
 3 | further comprising ~~the step of~~ using a quick-onset, short-acting
 4 | non-steroidal anti-inflammatory agent.

1 95. (withdrawn, currently amended) The method of claim 94,
 2 | ~~said step of~~ using said quick-onset, short-acting non-steroidal
 3 | anti-inflammatory agent further comprising ~~the step of~~ using
 4 | *ketoprofen*.

1 96. (withdrawn, currently amended) The method of claim 95,
 2 | further comprising ~~the step of~~:
 3 | using a clinical concentration of said *ketoprofen*, of at
 4 | least approximately 5%; and
 5 | said clinical concentration of said *ketoprofen*, of at most
 6 | approximately 20%.

1 97. (withdrawn, currently amended) The method of claim 96,
 2 | further comprising ~~the step of~~ using said clinical concentration
 3 | of said *ketoprofen*, of approximately 10%.

1 98. (withdrawn, currently amended) The method of claim 94,
 2 | ~~said step of~~ using said quick-onset, short-acting non-steroidal
 3 | anti-inflammatory agent further comprising ~~the step of~~ using a
 4 | quick-onset, short-acting non-steroidal anti-inflammatory agent
 5 | selected from the quick-onset, short-acting non-steroidal anti-
 6 | inflammatory agent group consisting of: *diclofenac*, *diflunisal*,
 7 | *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and
 8 | *tolmetin*.

1 99. (withdrawn, currently amended) The method of claim 88,
 2 | ~~said step of~~ using said therapeutic pain-relieving agent further
 3 | ~~comprising the step of~~ using a long-acting non-steroidal anti-
 4 | inflammatory agent.

1 100. (withdrawn, currently amended) The method of claim 99,
 2 | ~~said step of~~ using said long-acting non-steroidal anti-
 3 | inflammatory agent further ~~comprising the step of~~ using
 4 | *piroxicam*.

1 101. (withdrawn, currently amended) The method of claim 100,
 2 | further ~~comprising the steps of~~:
 3 | using a clinical concentration of said *piroxicam*, of at
 4 | least approximately 0.5%; and
 5 | using said clinical concentration of said *piroxicam*, of at
 6 | most approximately 4%.

1 102. (withdrawn, currently amended) The method of claim 101,
 2 | further ~~comprising the step of~~ using said clinical concentration
 3 | of said *piroxicam*, of approximately 1.0%.

1 103. (withdrawn, currently amended) The method of claim 99,
 2 | ~~said step of~~ using said long-acting non-steroidal anti-
 3 | inflammatory agent further ~~comprising the step of~~ using a long-
 4 | acting non-steroidal anti-inflammatory agent selected from the
 5 | long-acting non-steroidal anti-inflammatory agent group
 6 | consisting of: *celecoxib*, *meloxicam*, *nabumetone*, *naproxen*,
 7 | *oxaprozin*, *rofecoxib*, *sulindac*, and *valdecoxib*.

1 104. (withdrawn, currently amended) The method of claim 88,
 2 | ~~said step of~~ using said therapeutic pain-relieving agent further
 3 | ~~comprising the steps of:~~
 4 | using a local anesthetic; and
 5 | using a quick-onset, short-acting non-steroidal anti-
 6 | inflammatory agent.

1 105. (withdrawn, currently amended) The method of claim 104:
 2 | ~~said step of~~ using said local anesthetic further comprising-
 3 | ~~the step of~~ using *bupivacaine*; and
 4 | ~~said step of~~ using said quick-onset, short-acting non-
 5 | steroidal anti-inflammatory agent further comprising ~~the step of~~
 6 | using *ketoprofen*.

1 106. (withdrawn, currently amended) The method of claim 88,
 2 | ~~said step of~~ using said therapeutic pain-relieving agent further
 3 | ~~comprising the steps of::~~
 4 | using a local anesthetic; and
 5 | using a long-acting non-steroidal anti-inflammatory agent.

1 107. (withdrawn, currently amended) The method of claim 106:
 2 | ~~said step of~~ using said local anesthetic further comprising-
 3 | ~~the step of~~ using *bupivacaine*; and
 4 | ~~said step of~~ using said long-acting non-steroidal anti-
 5 | inflammatory agent further comprising ~~the step of~~ using
 6 | *piroxicam*.

1 108. (withdrawn, currently amended) The method of claim 88,

~~said step of~~ using said therapeutic pain-relieving agent further
comprising ~~the steps of~~:

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

109. (withdrawn, currently amended) The method of claim 108:

~~said step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~
using *ketoprofen*; and

~~said step of~~ using said long-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~ using
piroxicam.

110. (withdrawn, currently amended) The method of claim 88,

~~said step of~~ using said therapeutic pain-relieving agent further
comprising ~~the steps of~~:

using a local anesthetic;

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

111. (withdrawn, currently amended) The method of claim 110:

~~said step of~~ using said local anesthetic further comprising
~~the step of~~ using *bupivacaine*;

~~said step of~~ using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising ~~the step of~~

6 using *ketoprofen*; and

7 | ~~said step of~~ using said long-acting non-steroidal anti-
8 | inflammatory agent further comprising ~~the step of~~ using
9 | *piroxicam*.

1 112. (withdrawn, currently amended) The method of claim 111,
2 | further comprising ~~the steps of~~:

3 using a clinical concentration of said *bupivacaine*, of at
4 least approximately 2%;

5 using said clinical concentration of said *bupivacaine*, of
6 at most approximately 10%;

7 using a clinical concentration of said *ketoprofen*, of at
8 least approximately 5%;

9 using said clinical concentration of said *ketoprofen*, of at
10 most approximately 20%;

11 using a clinical concentration of said *piroxicam*, of at
12 least approximately 0.5%; and

13 using said clinical concentration of said *piroxicam*, of at
14 most approximately 4%.

1 113. (withdrawn, currently amended) The method of claim 112,
2 | further comprising ~~the steps of~~:

3 using said clinical concentration of said *bupivacaine*, of
4 approximately 5%;

5 using said clinical concentration of said *ketoprofen*, of
6 approximately 10%; and

7 using said clinical concentration of said *piroxicam*, of
8 approximately 1.0%.

1 114. (withdrawn, currently amended) The method of claim 87,
2 particularly for treating a viral disease:

3 ~~said step of~~ using said therapeutic agent further
4 ~~comprising the step of~~ using an antiviral agent; further
5 ~~comprising the steps of:~~

6 using said penetration enhancer for facilitating
7 penetration of said antiviral agent and said vasoconstrictor
8 through the patient's skin; and

9 using said vasoconstrictor for retarding vascular
10 dispersion of said antiviral agent.

1 115. (withdrawn, currently amended) The method of claim 114,
2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 ~~step of~~ using *2-deoxy-d-glucose*.

1 116. (withdrawn, currently amended) The method of claim 115,
2 further comprising ~~the steps of:~~

3 using a clinical concentration of said *2-deoxy-d-glucose*,
4 of at least approximately 0.1%; and

5 using said clinical concentration of said *2-deoxy-d-*
6 *glucose*, of at most approximately 0.4%.

1 117. (withdrawn, currently amended) The method of claim 116,
2 further comprising ~~the step of:~~

3 using said clinical concentration of said *2-deoxy-d-*

4 glucose, of approximately 0.2%.

1 118. (withdrawn, currently amended) The method of claim 114,
 2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
 3 ~~step of~~ using an antiviral agent selected from the antiviral
 4 agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*,
 5 and *docosanol*.

1 119. (withdrawn, currently amended) The method of claim 88,
 2 particularly for relieving pain from a viral disease and
 3 treating the viral disease:

4 ~~said step of~~ using said therapeutic agent further
 5 ~~comprising the step of~~ using an antiviral agent; further
 6 ~~comprising the steps of~~:
 7 using said penetration enhancer for further facilitating
 8 penetration of said antiviral agent through the patient's skin;
 9 and

10 using said vasoconstrictor for further retarding vascular
 11 dispersion of said antiviral agent.

1 120. (withdrawn, currently amended) The method of claim 119,
 2 ~~said step of~~ using said antiviral agent further comprising ~~the~~
 3 ~~step of~~ using 2-deoxy-d-glucose.

1 121. (withdrawn, currently amended) The method of claim 120,
 2 further comprising ~~the steps of~~:
 3 using a clinical concentration of said 2-deoxy-d-glucose,
 4 of at least approximately 0.1%; and

5 using said clinical concentration of said 2-deoxy-d-
6 *glucose*, of at most approximately 0.4%.

1 122. (withdrawn, currently amended) The method of claim 121,
2 | further comprising ~~the step of~~:

3 using said clinical concentration of said 2-deoxy-d-
4 *glucose*, of approximately 0.2%.

1 123. (withdrawn, currently amended) The method of claim 119,
2 | ~~said step of~~ using said antiviral agent further comprising ~~the~~
3 | ~~step of~~ using an antiviral agent selected from the antiviral
4 agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*,
5 and *docosanol*.

1 124. (withdrawn, currently amended) The method of claim 110:
2 | ~~said step of~~ using said vasoconstrictor further comprising-
3 | ~~the step of~~ using *phenylephrine*;
4 ~~said step of~~ using said penetration enhancer further
5 comprising ~~the step of~~ using a penetration enhancing agent
6 selected from the penetration-enhancing agent group consisting
7 of *dimethylsulfoxide* and *lecithin*;

8 | ~~said step of~~ using said local anesthetic further comprising-
9 | ~~the step of~~ using *bupivacaine*;

10 | ~~said step of~~ using said quick-onset, short-acting non-
11 steroidal anti-inflammatory agent further comprising ~~the step of~~
12 using *ketoprofen*; and

13 | ~~said step of~~ using said long-acting non-steroidal anti-

14 | inflammatory agent further comprising ~~the step of~~ using
 15 | *piroxicam*.

1 125. (withdrawn, currently amended) The method of claim 124,

2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *phenylephrine*, of at
 4 | least approximately 0.125%;

5 | using said clinical concentration of said *phenylephrine*, of
 6 | at most approximately 1.0%;

7 | using a clinical concentration of said *dimethylsulfoxide*,
 8 | of at most approximately 10%;

9 | using a clinical concentration of said *lecithin*, of at most
 10 | approximately 50%;

11 | using a clinical concentration of said *bupivacaine*, of at
 12 | least approximately 2%;

13 | using said clinical concentration of said *bupivacaine*, of
 14 | at most approximately 10%;

15 | using a clinical concentration of said *ketoprofen*, of at
 16 | least approximately 5%;

17 | using said clinical concentration of said *ketoprofen*, of at
 18 | most approximately 20%;

19 | using a clinical concentration of said *piroxicam*, of at
 20 | least approximately 0.5%; and

21 | using said clinical concentration of said *piroxicam*, of at
 22 | most approximately 4%.

1 126. (withdrawn, currently amended) The method of claim 125,
 2 further comprising ~~the steps of~~:
 3 using said clinical concentration of said *phenylephrine*, of
 4 approximately 0.5%;
 5 using said clinical concentration of said *bupivacaine*, of
 6 approximately 5%;
 7 using said clinical concentration of said *ketoprofen*, of
 8 approximately 10%; and
 9 using said clinical concentration of said *piroxicam*, of
 10 approximately 1.0%.

1 127. (withdrawn, currently amended) The method of claim 110,
 2 additionally for treating a viral disease, ~~said step of~~ using
 3 said therapeutic agent further comprising ~~the step of~~ using an
 4 antiviral agent.

1 128. (withdrawn, currently amended) The method of claim 127:
 2 ~~said step of~~ using said vasoconstrictor further comprising-
 3 ~~the step of~~ using *phenylephrine*;
 4 ~~said step of~~ using said penetration enhancer further
 5 comprising ~~the step of~~ using a penetration enhancing agent
 6 selected from the penetration-enhancing agent group consisting
 7 of *dimethylsulfoxide* and *lecithin*;
 8 ~~said step of~~ using said local anesthetic further comprising-
 9 ~~the step of~~ using *bupivacaine*;
 10 ~~said step of~~ using said quick-onset, short-acting non-

11 | steroidal anti-inflammatory agent further comprising ~~the step of~~
 12 | using *ketoprofen*;

13 | ~~said step of~~ using said long-acting non-steroidal anti-
 14 | inflammatory agent further comprising ~~the step of~~ using
 15 | *piroxicam*; and

16 | ~~said step of~~ using said antiviral agent further comprising-
 17 | ~~the step of~~ using 2-deoxy-d-glucose.

1 | 129. (withdrawn, currently amended) The method of claim 128,

2 | further comprising ~~the steps of~~:

3 | using a clinical concentration of said *phenylephrine*, of at
 4 | least approximately 0.125%;

5 | using said clinical concentration of said *phenylephrine*, of
 6 | at most approximately 1.0%;

7 | using a clinical concentration of said *dimethylsulfoxide*,
 8 | of at most approximately 10%;

9 | using a clinical concentration of said *lecithin*, of at most
 10 | approximately 50%;

11 | using a clinical concentration of said *bupivacaine*, of at
 12 | least approximately 2%;

13 | using said clinical concentration of said *bupivacaine*, of
 14 | at most approximately 10%;

15 | using a clinical concentration of said *ketoprofen*, of at
 16 | least approximately 5%;

17 | using said clinical concentration of said *ketoprofen*, of at

18 most approximately 20%;
 19 using a clinical concentration of said *piroxicam*, of at
 20 least approximately 0.5%;
 21 using said clinical concentration of said *piroxicam*, of at
 22 most approximately 4%;
 23 using a clinical concentration of said *2-deoxy-d-glucose*,
 24 of at least approximately 0.1%; and
 25 using said clinical concentration of said *2-deoxy-d-*
 26 *glucose*, of at most approximately 0.4%.

1 130. (withdrawn, currently amended) The method of claim 129,
 2 | ~~further comprising the steps of:~~
 3 | using said clinical concentration of said *phenylephrine*, of
 4 | approximately 0.5%;
 5 | using said clinical concentration of said *bupivacaine*, of
 6 | approximately 5%;
 7 | using said clinical concentration of said *ketoprofen*, of
 8 | approximately 10%;
 9 | using said clinical concentration of said *piroxicam*, of
 10 | approximately 1.0%; and
 11 | using said clinical concentration of said *2-deoxy-d-*
 12 | *glucose*, of approximately 0.2%.

1 131. (withdrawn, currently amended) The method of claim 66,
 2 | ~~further comprising the step of:~~
 3 | applying said vasoconstrictor and said penetration enhancer

4 to the patient's skin.

1 132. (withdrawn, currently amended) The method of claim 78,

2 further comprising ~~the step of~~:

3 applying said *phenylephrine* and said *dimethylsulfoxide* to
4 the patient's skin.

1 133. (withdrawn, currently amended) The method of claim 82,

2 further comprising ~~the step of~~:

3 applying said *phenylephrine* and said *lecithin* to the
4 patient's skin.

1 134. (withdrawn, currently amended) The method of claim 87,

2 further comprising ~~the step of~~:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic agent to the patient's skin.

1 135. (withdrawn, currently amended) The method of claim 88,

2 further comprising ~~the step of~~:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said therapeutic pain-relieving agent to the patient's skin.

1 136. (withdrawn, currently amended) The method of claim 89,

2 further comprising ~~the step of~~:

3 applying said vasoconstrictor, said penetration enhancer,
4 and said local anesthetic to the patient's skin.

1 137. (withdrawn, currently amended) The method of claim 90,

2 further comprising ~~the step of~~:

3 applying said vasoconstrictor, said penetration enhancer,

4 and said *bupivacaine* to the patient's skin.

1 138. (withdrawn, currently amended) The method of claim 94,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,

4 and said quick-onset, short-acting non-steroidal anti-

5 inflammatory agent to the patient's skin.

1 139. (withdrawn, currently amended) The method of claim 95,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,

4 and said *ketoprofen* to the patient's skin.

1 140. (withdrawn, currently amended) The method of claim 99,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,

4 and said long-acting non-steroidal anti-inflammatory agent to

5 the patient's skin.

1 141. (withdrawn, currently amended) The method of claim 100,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,

4 and said *piroxicam* to the patient's skin.

1 142. (withdrawn, currently amended) The method of claim 110,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,

4 said local anesthetic, said quick-onset, short-acting non-

5 steroidal anti-inflammatory agent, and said long-acting non-

6 steroidal anti-inflammatory agent to the patient's skin.

1 143. (withdrawn, currently amended) The method of claim 111,

2 | ~~further comprising the step of:~~

3 applying said vasoconstrictor, said penetration enhancer,

4 said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the

5 patient's skin.

1 144. (withdrawn, currently amended) The method of claim 114,

2 | ~~further comprising the step of:~~

3 applying said vasoconstrictor, said penetration enhancer,

4 and said antiviral agent to the patient's skin.

1 145. (withdrawn, currently amended) The method of claim 115,

2 | ~~further comprising the step of:~~

3 applying said vasoconstrictor, said penetration enhancer,

4 and said *2-deoxy-d-glucose* to the patient's skin.

1 146. (withdrawn, currently amended) The method of claim 119,

2 | ~~further comprising the step of:~~

3 applying said vasoconstrictor, said penetration enhancer,

4 therapeutic pain-relieving agent, and said antiviral agent to

5 the patient's skin.

1 147. (withdrawn, currently amended) The method of claim 120,

2 | ~~further comprising the step of:~~

3 applying said vasoconstrictor, said penetration enhancer,

4 therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to

5 the patient's skin.

1 148. (withdrawn, currently amended) The method of claim 124,

2 | further comprising ~~the step of~~:

3 | applying said *phenylephrine*, said penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 said *ketoprofen*, and said *piroxicam* to the patient's skin.

1 149. (withdrawn, currently amended) The method of claim 127,

2 | further comprising ~~the step of~~:

3 | applying said vasoconstrictor, said penetration enhancer,
4 said local anesthetic, said quick-onset, short-acting non-
5 steroidal anti-inflammatory agent, said long-acting non-
6 steroidal anti-inflammatory agent, and said antiviral agent to
7 the patient's skin.

1 150. (withdrawn, currently amended) The method of claim 128,

2 | further comprising ~~the step of~~:

3 | applying said *phenylephrine*, said penetration enhancing
4 agent selected from the penetration-enhancing agent group
5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,
6 said *ketoprofen*, said *piroxicam*;; and said *2-deoxy-d-glucose* to
7 the patient's skin.